Regulatory PathRegulatory requirements compared

Active substance

Trientine tetrahydrochloride

Open in the medicines table

SFDA Saudi Arabia — SFDA human drug list

Trade nameStrengthForm · routePackPublic priceTypeCompanyStatus
Cuprior150 mgFilm-coated tablet · Oral use72 BlisterSAR 7303.80NCE · PrescriptionOrphalanValid
Indications — CHI Daman Drug Formulary

WILSON'S DISEASE

US FDA United States — FDA approvals (Drugs@FDA)

ProductStrengthForm · routeApplicantStatusFirst approved
CUVRIOR300MGtablet · oralORPHALANPrescription28 Apr 2022

EMA European Union — centrally authorised medicines

Cuprior Orphalan · Authorised · authorised 5 Sep 2017 · ATC A16AX

Therapeutic indication (EMA)

Cuprior is indicated for the treatment of Wilson's disease in adults, adolescents and children ≥ 5 years intolerant to D-penicillamine therapy.

Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.